Bubs Australia (BUB) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
13 Jan, 2026Opening remarks and agenda
Meeting opened with acknowledgment of traditional land custodians, introductions of board, executives, auditors, and share registry representatives, and procedural matters.
Notice of meeting and voting procedures explained, with all resolutions to be decided by poll.
Six items of business were scheduled, including five shareholder resolutions (one withdrawn).
CEO and Managing Director presented FY24 results, regional performance, and FY25 outlook and profitability path.
Financial performance review
Achieved FY24 net revenue of AUD 80 million, up 34% YoY, with strong growth in US (46%), China (27%), and Australia (24%).
Gross margin improved to over 41%, exceeding target, and EBITDA loss reduced from AUD 105 million to AUD 20 million.
Net loss after tax improved to AUD 21 million from AUD 108 million.
Operating expenses as a percentage of revenue dropped from 92% to 74%, with further reductions targeted.
Cash burn normalized to AUD 1.2 million per month, with significant one-off costs in FY24 and improved working capital management.
Raised AUD 17.4 million in Dec 2023 to fund growth, regulatory costs, and inventory build.
Inventory and receivables increased to support growth and mitigate stock shortages.
Board and executive committee updates
CEO and Managing Director Reg Weine led the turnaround for 14 months, supported by a strong executive team.
Ms Katrina Rathie re-elected as non-executive director with 93.86% support.
Approval granted for CEO Reginald Weine's long-term incentive performance rights.
Company Secretary Jay Stephenson recognized for eight years of service, stepping down after the meeting.
Latest events from Bubs Australia
- FY26 revenue guidance raised to $120–125M with double-digit growth and strong EBITDA outlook.BUB
Status update26 Mar 2026 - Revenue up 14% to $55.5M, led by US growth; gross margin 48%; FY26 outlook upgraded.BUB
H1 202627 Feb 2026 - Revenue up 34% to $80m, with strong US/China growth and positive FY2025 outlook.BUB
H2 202423 Jan 2026 - Net profit of AUD 3.6M and 23% revenue growth, but FDA and funding risks remain.BUB
H1 20253 Dec 2025 - Revenue up 29% to $102.5M, USA leads growth, positive EBITDA, and FDA submission for US access.BUB
H2 202523 Nov 2025 - Strong FY25 growth, global expansion, and strategic focus on FDA and China drive outlook.BUB
AGM 202520 Nov 2025 - Net revenue up 30% to $25.6m, EBITDA positive, and $22.9m in liquidity at quarter end.BUB
Q1 2026 TU30 Oct 2025 - FY25 saw 29% revenue growth, positive EBITDA, and strong US and China market performance.BUB
Q4 2025 TU28 Jul 2025